Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor Efficacy

By sjmartinez • July 11, 2022

Lechner MG, Cheng MI, Patel AY, Hoang AT, Yakobian N, Astourian M, Pioso MS, Rodriguez ED, McCarthy EC, Hugo W, Angell TE, Drakaki A, Ribas A, Su MA. Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor Efficacy. J Immunol. 2022 Jul 11:ji2200244. doi: 10.4049/jimmunol.2200244. Epub ahead of print. PMID: 35817515.

Tags: Endocrinology, Hematology/Oncology, Publications

Phosphate Binder Impairs Levothyroxine Absorption in a Hypothyroid Patient With End-Stage Renal Disease

Ko M, Barai R, Brent G. Phosphate Binder Impairs Levothyroxine Absorption in a Hypothyroid Patient With End-Stage Renal Disease. Cureus. 2024 Oct 15;16(10):e71551. doi: 10.7759/cureus.71551.[...]

Association of BRAF V600E allele frequency with clinicopathologic outcomes in papillary thyroid cancer

Schumm MA, Nikiforov YE, Nikiforova MN, Wald AI, Tseng CH, Smooke-Praw S, Wu JX, Yeh MW, Livhits MJ. Association of BRAF V600E allele frequency with[...]

The Relationship Between Hospital Safety-Net Burden on Outcomes for High-Volume Thyroid Cancer Surgeons

Huston-Paterson HH, Mao YV, Tseng CH, Kim J, Chen DW, Wu JX, Yeh MW. The Relationship Between Hospital Safety-Net Burden on Outcomes for High-Volume Thyroid[...]